Merck Rotateq pricing: CDC estimates the cost-effective ceiling for a three-dose vaccination series of Merck's pending rotavirus vaccine is $67, the agency reported to its Advisory Committee on Immunization Practices Oct. 27. Merck has not set a price for the vaccine, but said it is committed to a level that will assure widespread use and availability. CDC predicts cost-effectiveness of a routine vaccination schedule for Rotateq would be in the same range as Sanofi-Aventis' meningococcal vaccine Menactra. ACIP's rotavirus vaccine working group is recommending universal administration of three doses of the vaccine at two, four and six months of age. Merck expects approval of Rotateq in early 2006. GlaxoSmithKline said it is in discussions with FDA about licensing its rotavirus vaccine Rotarix in the U.S...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.
HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.
The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.